WO2006138320A2 - Procede permettant un enrobage peroperatoire d'agents therapeutiques sur des sutures, sutures composites, et procedes d'utilisation associes - Google Patents

Procede permettant un enrobage peroperatoire d'agents therapeutiques sur des sutures, sutures composites, et procedes d'utilisation associes Download PDF

Info

Publication number
WO2006138320A2
WO2006138320A2 PCT/US2006/023017 US2006023017W WO2006138320A2 WO 2006138320 A2 WO2006138320 A2 WO 2006138320A2 US 2006023017 W US2006023017 W US 2006023017W WO 2006138320 A2 WO2006138320 A2 WO 2006138320A2
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
suture
vessel
growth factor
composite
Prior art date
Application number
PCT/US2006/023017
Other languages
English (en)
Other versions
WO2006138320A3 (fr
Inventor
Rita Prajapati
Mark Timmer
Patrick De Deyne
Joseph Hammer
Chunlin Yang
Steven Bowman
Original Assignee
Depuy Spine, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/153,285 external-priority patent/US20060286289A1/en
Priority claimed from US11/315,793 external-priority patent/US20060287675A1/en
Priority claimed from US11/315,905 external-priority patent/US20060287676A1/en
Application filed by Depuy Spine, Inc filed Critical Depuy Spine, Inc
Publication of WO2006138320A2 publication Critical patent/WO2006138320A2/fr
Publication of WO2006138320A3 publication Critical patent/WO2006138320A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06166—Sutures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/14—Post-treatment to improve physical properties
    • A61L17/145—Coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective

Definitions

  • rhGDF-5 for its ability to form tendon, cartilage, bone and ligament-like structures.
  • Rickert et al., Growth Factors, 19, 2001 , 115-126 discloses the use of recombinant human Growth and Differentiation Factor-5 (rhGDF-5) upon sutures to stimulate tendon healing in an Achilles tendon model in rats.
  • rhGDF-5 recombinant human Growth and Differentiation Factor-5
  • the method of coating the rhGDF-5 to the sutures is described as simple pipetting of a solution containing rhGDF-5 onto the suture.
  • the literature in general does not disclose methods of coating growth factors onto sutures. See for example, US Patent Nos.
  • Sutures coated with antimicrobials are commercially available for clinical use.
  • polyglactin sutures coated with antibiotics sold under the tradename Coated VICRYL PLUS (polyglactin 910) Suture (Ethicon, Somerville, NJ) is the first and only antibacterial suture approved by the FDA for inhibiting the colonization of bacteria, which causes the majority of surgical site infections.
  • VICRYL PLUS suture creates an inhibitory zone around the suture in which bacteria are prevented from making colonies. See Rothenberger, Surgical Infection Society Journal (Supp) Dec. 2002, pp. 579-87, and Mangram, Infection control and Hospital Epidemiology , 1999, 20(40, 247-280.
  • VICRYL PLUS suture contains a bacteriostat sold under the tradename IRGACARE MP* (Ciba Specialty Chemicals Corp., Tarrytown, NY), the most pure form of triclosan, a proven, broad spectrum antibacterial drug used effectively in consumer products for more than 30 years. VICRYL PLUS suture is indicated for use in general soft tissue approximation and/or ligation, except for ophthalmic, cardiovascular and neurological tissues.
  • the present inventors have developed a number of devices and procedures for the intra-operative coating of sutures with therapeutic agents such as growth factors.
  • a method of coating a suture comprising the steps of: a) providing a device containing a therapeutic agent, and b) contacting the suture to the device.
  • a therapeutic agent such as a lyophilized growth factor
  • a vessel having a porous body (such as a sponge) at one end and a fluid (such as saline) is introduced into the vessel to form a solution comprising the therapeutic agent that also wets the sponge.
  • a fluid such as saline
  • the wetted porous body may then be contacted with a suture to coat the suture with the solution.
  • a device for coating a suture comprising:
  • an applicator has a porous body (such as a sponge) at one end while the fluid (such as a saline solution) and the therapeutic agent (such as a lyophilized growth factor) are separated within the vessel by a breakable seal.
  • the seal is broken thereby allowing to reconstitute the therapeutic agent into a solution, which subsequently wets the porous body.
  • the wet porous body may then be used to coat a suture or other implant.
  • a device for coating a suture comprising:
  • a vessel having an open end and an inner wall, b) a porous body enclosing the open end of the vessel; c) a breakable seal disposed upon the inner wall of the vessel defining a first chamber and a second chamber, d) a fluid contained within the first chamber, and e) a therapeutic protein contained within the second chamber.
  • a method of coating a suture comprising the steps of: a) providing the device of the second embodiment containing a therapeutic agent, b) breaking the seal between the chamber to mix the fluid and the therapeutic agent and wet the porous body, and c) contacting the suture with the wetted porous body.
  • an applicator has a roller ball at one end and a chamber containing a fluid comprising the therapeutic agent (such as a solution comprising a growth factor).
  • a suture is passed along the periphery of the roller ball that contacts the solution, thereby coating the suture.
  • a device for coating a suture comprising: a) a vessel having an open end having an opening, a closed end, and an inner wall defining a chamber, b) a roller ball disposed within the opening; c) an entry recess and an exit recess extending into the inner wall at the opening, d) a fluid comprising a therapeutic agent contained within the chamber, and e) a suture having i) a first end portion extending out of the entry recess, ii) an intermediate portion passing through the vessel and contacting the solution and iii) a second end portion exiting the vessel through the exit recess.
  • a method of coating a suture comprising the steps of:
  • a fluid such as a thermoreversible gel loaded with growth factor is contained within a vessel having two opposing openings in its opposing end portions.
  • a suture is passed through the fluid via each opening, thereby coating the suture.
  • the fluid is a thermoreversible gel, it coats the suture in its liquid state and then solidifies on the suture in its gel state.
  • a device for coating a suture comprising: a) a vessel having a first open end and a second open end, and a chamber therebetween, b) a fluid comprising a therapeutic agent contained within the chamber of the vessel, and c) a suture having i) a first end portion extending out of the first open end, ii) an intermediate portion passing through the chamber and contacting the fluid and iii) a second end portion exiting the vessel through the second open end.
  • a method of coating a suture comprising the steps of:
  • a squeezable container having an opening.
  • the therapeutic agent is forced out of the opening and onto the suture.
  • a device for coating a suture comprising: a) a vessel having a flexible wall defining a chamber, an end surface, and a first opening in the end surface in fluid communication with the chamber, and b) a fluid containing a therapeutic protein contained within the chamber of the vessel.
  • the present invention offers a novel method for creating coated sutures intra- operatively. In addition, it provides surgeons with the flexibility to (i) determine the desired amount of therapeutic agent to administer, and (ii) to select the length of suture that requires coating. Moreover, the present invention will provide many advantages over the conventional methods of coating sutures:
  • the present invention will provide the surgeon with an ability to vary the dose of the therapeutic agent present on the suture.
  • the present invention will provide the surgeon with the ability to coat sutures of different sizes and needles types. This allows the surgeon to coat portions of a single suture with the therapeutic agent (such as a growth factor), more specifically in areas where its contact with the host tissue is intended to have a therapeutic effect and leave other portions of the same suture uncoated.
  • the present invention will provide the surgeon with the potential for providing sterile long-term storage of vials of therapeutic agents (such as growth factors like rhGDF-5) at either frozen, refrigerated or at room temperature.
  • the present invention will provide the surgeon with the potential for providing growth factor-coated sutures for soft tissue repair, such as but not limited to repair of anterior cruciate ligament (ACL), medial collateral ligament of the knee or elbow, reconstruction of the anterior shoulder capsule to enhance anterior stability, reattachment of tendons especially near the bony insertion, reconstruction of the lateral joint capsule of the ankle, meniscus, Achilles tendon and rotator cuff tears.
  • ACL anterior cruciate ligament
  • the present invention will provide the surgeon with the potential for providing new ways of using therapeutic agents such as growth factors independent of a specific implant.
  • FIGS 1a-1d are cross-sections of the first embodiment of the present invention, whereby a fluid is introduced in a vessel containing a therapeutic agent and the resulting solution is applied through a porous body.
  • FIGS 2a-2d are cross-sections of the second embodiment of the present invention, whereby a fluid and a therapeutic agent are separated in the same vessel by a breakable seal.
  • FIGS. 3a and 3b are cross-sections of the third embodiment of the present invention, whereby a roller ball assists in the movement of a suture through a vessel containing a solution comprising a therapeutic agent.
  • FIG. 4 is a cross-section of the fourth embodiment of the present invention, whereby a suture is pulled through a vessel containing a fluid containing a therapeutic agent.
  • FIG. 5 is a cross-section of a fifth embodiment of the present invention, wherein a vessel having a flexible wall is squeezed to push a fluid containing a therapeutic agent through an opening in the vessel.
  • FIG. 6 describes a woven composite suture comprising a first suture comprising collagen and a second suture.
  • FIG. 7 describes a composite mesh comprising a first plurality of suture comprising collagen and a second plurality of sutures.
  • FIGS. 8a-8d are cross-sections of another embodiment of the present invention, whereby a therapeutic agent is provided on or within a porous body.
  • a device 1 for coating a suture comprising: a) a vessel 3 having an open end 5, b) a porous body 7 (such as a sponge) enclosing the open end of the vessel; and c) a therapeutic agent (such as a growth factor) 9 contained within the vessel.
  • a sterile vial contains a lyophilized growth factor such as rhGDF-5.
  • a lyophilized growth factor such as rhGDF-5.
  • the vial Prior to use, the vial is stored at frozen, refrigerated or at room temperature so as to avoid denaturing the protein.
  • the lyophilized rhGDF-5 is reconstituted with a sterile diluent 10 (such as saline), that has been introduced through the sponge, for example, through a syringe 11 to the desired concentration.
  • the vial is gently mixed. Then, the vial is inverted to allow the solution to soak into the sterile sponge that is present at the open end of the vial.
  • the sterile sponge is the type used in a DERMABONDTM Topical Skin Adhesive applicator (Closure Medical Corp., Raleigh, NC).
  • a sterile suture is then placed or rubbed over the saturated sponge to coat the suture with rhGDF-5.
  • the sponge has a recess 13 through which the suture 15 is passed to allow for peripheral coating of the suture.
  • the sutures are then air-dried to remove the water from the saline solution, thereby leaving rhGDF-5 adhered to the suture.
  • the coated suture can then be used immediately for surgery.
  • thermoreversible gel is used as the fluid.
  • a vessel 21 having an open end 23, a closed end 25 and an inner wall
  • a porous body 29 such as a sponge
  • a breakable seal 31 disposed upon the inner wall of the vessel defining a first chamber 33 and a second chamber 35, d) a fluid 37 contained within the first chamber, and e) a therapeutic agent 39 contained within the second chamber.
  • lyophilized rhGDF-5 is the therapeutic agent that is placed in a sterile, flexible vial having a breakable seal that defines two chambers.
  • the rhGDF-5 is stored in one chamber and the second chamber contains a predetermined volume of a fluid such as sterile saline or a thermoreversible gel.
  • the flexible vial is squeezed at the location of the breakable seal, thereby breaking the seal between the two chambers and allowing communication between the two chambers and allowing the materials in the chambers to mix.
  • the vial is gently inverted to allow the rhGDF-5 containing solution to soak into the porous body (preferably a domed sponge similar to that of a DERMABOND R applicator).
  • the rhGDF-5 solution is released onto a suture 15 by placing pressure on the domed sponge.
  • the rhGDF-5 solution is released onto the sutures by applying constant pressure to the sponge. This ensures an even coverage of the suture.
  • the sutures are then air-dried to remove the water from the solution, thereby leaving rhGDF-5 adhered to the suture.
  • the coated suture can then be used immediately for surgery.
  • the sponge has a rounded outer surface 30 for ease of use.
  • a device 51 for coating a suture comprising:
  • a vessel 53 having an open end 55 having an opening 56, a closed end 57, and an inner wall 59 defining a chamber 58, b) a roller ball 65 disposed within the opening; c) an entry recess 61 and an exit recess 63 extending into the inner wall at the opening, d) a fluid 67 comprising a therapeutic agent contained within the chamber, and e) a suture 71 having i) a first end portion 73 extending out of the entry recess, ii) an intermediate portion 75 passing through the vessel and contacting the solution and iii) a second end portion 77 exiting the vessel through the exit recess.
  • rhGDF-5 is the therapeutic agent and is present in a reconstituted form in a vessel 53 with sterile saline. As the sutures are pulled through, they are evenly coated with rhGDF-5. The sutures are then air-dried to remove the water from the solution, thereby leaving rhGDF-5 adhered to the suture. The coated suture can then be used immediately for surgery.
  • the inner wall of this device has a concave curve (not shown) at the open end of the vessel.
  • the entry and exit recesses are substantially opposite one another at the open end of the vessel.
  • the second end portion of the suture is contained on a roll (not shown).
  • the inner wall has a diameter at the open end that is slightly larger than the diameter of the roller ball.
  • a device 101 for coating a suture comprising:
  • a vessel 103 having a longitudinal axis, a first open end 105 and a second open end 106, and a chamber 107 therebetween, b) first 111 and second 113 septa respectively enclosing the first and second open ends, the first septum having a first hole 115 extending from the chamber to first open end and the second septum having a second hole 117 extending from the chamber to second open end, c) a fluid 119 (such as a thermoreversible gel) containing a therapeutic agent (such as a growth factor) contained within the chamber of the vessel, and d) a suture 121 having i) a first end portion 123 extending out of the first open end, ii) an intermediate portion 125 passing through the chamber and contacting the solution and iii) a second end portion 127 exiting the vessel through the second open end.
  • a fluid 119 such as a thermoreversible gel
  • a therapeutic agent such as a growth factor
  • the vessel is a vial that contains two septa at opposite ends. Contained in the vial is a sterile solution of rhGDF-5 and a thermoreversible gel.
  • the gelling point of the gel is above room temperature.
  • the vial is heated above the gelling point of the gel to liquify it.
  • the suture is passed through the vial via the septum to insure an even coating.
  • the suture may be attached to a needle and the needle is passed through the septa before the suture. Once the liquefied solution emerges from the vial, the coating solidifies on the suture as its temperature proceeds to room temperature. The suture is then immediately used in surgery.
  • thermoreversible gel is a medical grade gelatin.
  • the gelation point of the gelatin is about 30 0 C.
  • the first and second holes are substantially opposite one another along the longitudinal axis.
  • a device 201 for coating a suture comprising:
  • a vessel 203 having a bottom surface, 205, a top surface 207, a flexible wall 204 therebetween defining first 211 and second 213 edges with the top surface and a chamber 206, a first opening 208 in the top surface in fluid communication with the chamber, and a linear recess 209 in the top surface that passes across the first opening and intersects the first and second edges, and b) a fluid 219 (such as a thermoreversible gel) containing a therapeutic agent (such as a growth factor) contained within the chamber of the vessel, and c) a cap 225 adapted to enclose the top surface of the vessel.
  • a fluid 219 such as a thermoreversible gel
  • a therapeutic agent such as a growth factor
  • the cap In use, the cap is removed from the top surface of the vessel to expose the first opening. A suture to be coated is placed along the linear recess in the top surface of the vessel. The flexible wall of the vessel is then squeezed to force fluid from the chamber to flow out of the first opening, thereby coating the suture in the vicinity of the opening. Other portions of the suture are then passed over the opening, guided by the linear recess, and are likewise coated.
  • the therapeutic agent to be coated upon the suture is a protein.
  • the therapeutic protein to be coated upon the suture is selected from the group consisting of growth factors, anti-microbials, analgesics, anti-inflammatory agents, anti-neoplasties, RGD sequences, fibrin and clotting factors.
  • the therapeutic agent to be coated upon the suture is selected from the group consisting of amino acids, anabolics, analgesics and antagonists, anaesthetics, anti-adrenergic agents, anti-asthmatics, anti- atherosclerotics, antibacterials, anticholesterolics, anti-coagulants, antidepressants, antidotes, anti-emetics, anti-epileptic drugs, anti-fibrinolytics, anti-inflammatory agents, antihypertensives, antimetabolites, antimigraine agents, antimycotics, antinauseants, antineoplastics, anti-obesity agents, antiprotozoals, antipsychotics, antirheumatics, antiseptics, antivertigo agents, antivirals, appetite stimulants, bacterial vaccines, bioflavonoids, calcium channel blockers, capillary stabilizing agents, coagulants, corticosteroids, detoxifying agents for cytostatic treatment, diagnostic agents (like contrast
  • the therapeutic agent to be coated upon the suture is a non-curing therapeutic agent.
  • Suitable fluids include aqueous liquids (such as saline) and gels that include, but are not limited to, hyaluronic acid, succinalyted collagen, carboxymethyl cellulose (CMC), gelatin, collagen gel, fibrinogen/thrombin, and liquid polymers (MGSA).
  • aqueous liquids such as saline
  • gels that include, but are not limited to, hyaluronic acid, succinalyted collagen, carboxymethyl cellulose (CMC), gelatin, collagen gel, fibrinogen/thrombin, and liquid polymers (MGSA).
  • Porous bodies suitable for use in the present invention include but are not limited to sponges, membranes, pads, non-woven materials, felt, meshes, knit meshes, woven materials and braided materials.
  • the sutures used in accordance with the present invention will be bioresorbable.
  • the sutures may also be non-resorbable.
  • Preferred bioresorbable materials which can be used to make the sutures of the present invention include bioresorbable polymers or copolymers, preferably selected from the group consisting of hydroxy acids, (particularly lactic acids and glycolic acids; caprolactone; hydroxybutyrate; dioxanone; orthoesters; orthocarbonates; and aminocarbonates).
  • Preferred bioresorbable materials also include natural materials such as chitosan, collagen, cellulose, fibrin, hyaluronic acid; fibronectin, and mixtures thereof.
  • bioresorbable materials are preferred because they can be manufactured under process specifications which insure repeatable properties, (see http://www.emedicine.com/derm/topic825.htm for listing of nonresorbable materials)
  • a variety of bioabsorbable polymers can be used to make the suture of the present invention.
  • suitable biocompatible, bioabsorbable polymers include but are not limited to polymers selected from the group consisting of aliphatic polyesters, poly(amino acids), copoly(ether-esters), polyalkylenes oxalates, polyamides, tyrosine derived polycarbonates, poly(iminocarbonates), polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(anhydrides), polyphosphazenes, biomolecules (i.e., biopolymers such as collagen, elastin, bioabsorbable starches, etc.) and blends thereof.
  • biomolecules i.e., biopolymers such as collagen, elastin, bioabsorbable starches, etc.
  • aliphatic polyesters include, but are not limited to, homopolymers and copolymers of lactide (which includes lactic acid, D-,L- and meso lactide), glycolide (including glycolic acid), ⁇ -caprolactone, p-dioxanone (1 ,4-dioxan-2-one), trimethylene carbonate (1 ,3-dioxan-2-one), alkyl derivatives of trimethylene carbonate, ⁇ - valerolactone, ⁇ -butyrolactone, ⁇ -butyrolactone, ⁇ -decalactone, hydroxybutyrate, hydroxyvalerate, 1 ,4-dioxepan-2-one (including its dimer 1,5,8,12- tetraoxacyclotetradecane-7,14-dione), 1 ,5-dioxepan-2-one, 6,6-dimethyl-1 ,4-dioxan-2- one, 2,5-dike
  • Poly(iminocarbonates), for the purpose of this invention are understood to include those polymers as described by Kemnitzer and Kohn, in the Handbook of Biodegradable Polymers, edited by Domb, et. al., Hardwood Academic Press, pp. 251- 272 (1997).
  • Copoly(ether-esters), for the purpose of this invention are understood to include those copolyester-ethers as described in the Journal of Biomaterials Research, Vol. 22, pages 993-1009, 1988 by Cohn and Younes, and in Polymer Preprints (ACS Division of Polymer Chemistry), Vol. 30(1), page 498, 1989 by Cohn (e.g. PEO/PLA).
  • Polyalkylene oxalates for the purpose of this invention, include those described in U.S. Patent Numbers 4,208,511 ; 4,141 ,087; 4,130,639; 4,140,678; 4,105,034; and 4,205,399.
  • Polyphosphazenes, co-, ter- and higher order mixed monomer-based polymers made from L-lactide, D,L-lactide, lactic acid, glycolide, glycolic acid, para- dioxanone, trimethylene carbonate and ⁇ -caprolactone such as are described by Allcock in The Encyclopedia of Polymer Science, Vol.
  • Polyanhydrides include those derived from diacids of the form HOOC- C6H4 -O-(CH2) m -O-C6H4-COOH, where m is an integer in the range of from 2 to 8, and copolymers thereof with aliphatic alpha-omega diacids of up to 12 carbons.
  • Polyoxaesters, polyoxaamides and polyoxaesters containing amines and/or amido groups are described in one or more of the following U.S. Patent Nos. 5,464,929;
  • the bioresorbable material is selected from the group consisting of poly(lactic acid) (“PLA”) and poly(glycolic acid)("PGA”), and copolymers thereof.
  • one of the resorbable sutures is selected from the group consisting of PLA, PGA 1 PLGA, PDS, PCL, and mixtures thereof.
  • the suture comprises collagen because rhGDF-5 has a high affinity towards collagen.
  • the suture comprises surgical gut, which comprises purified connective tissue (of which its main component is type I collagen) derived from either the serosal layer or the submucosal fibrous layer of bovine intestines.
  • a suture comprising collagen coated with rhGDF-5.
  • regular sterile sutures 151 are wrapped or interwoven with sterile surgical gut suture 153, and then this composite construct is coated with rhGDF-5 as per the first embodiment described above.
  • strands of surgical gut sutures 161 can be manufactured and/or interwoven with other synthetic fibers 163 to create a mesh or non-woven composite structure.
  • This mesh/non-woven composite would have enhanced binding collagen capacity on the surface for rhGDF-5 coating. Then, this mesh/non-woven composite construct is coated with rhGDF-5 as per the second embodiment described above.
  • a composite suture comprising a first suture comprising collagen (which is preferably surgical gut) and a second suture, wherein the composite suture is coated with rhGDF- 5.
  • gut suture is selected, in some embodiments, it is Plain Gut Suture - Surgical Gut Suture Absorbable, USP, available from Ethicon (Somerville, NJ) .
  • Plain gut suture is a strand of collagenous material prepared from the submucosal layers of the small intestine of healthy sheep, or from the serosal layers of the small intestine of healthy cattle. They are sterile and elicit only a slight to minimal tissue reaction during absorption. Fast absorbing surgical gut sutures differ from U. S. P. minimum strength requirements by less than 30%.
  • Chromic gut suture When gut suture is selected, in some embodiments, it is Chromic Gut Suture - Surgical Gut Suture Absorbable, USP, available from Ethicon (Somerville, NJ).
  • Chromic gut suture is an absorbable, sterile surgical suture composed of purified connective tissue (mostly collagen) derived from either the serosal layer of cow (bovine) or the submucosal fibrous layer of sheep (ovine) intestines.
  • Surgical gut sutures are available in plain or chromic. Chromic gut is processed to provide greater resistance to absorption. Surgical gut is packaged in tubing fluid. Blue dyed chromic gut suture is also available. Surgical gut suture meets all requireents established by the U.S. Pharmacopeia (U. S. P.) for absorbable surgical sutures.
  • composite sutures made up of at least two or more different types of sutures are coated with the therapeutic agents of the present invention.
  • the composite comprises a resorbable suture and a non-resorbable suture.
  • the composite comprises two different types of resorbable suture.
  • the composite comprises two different types of non-resorbable sutures.
  • non-resorbable sutures include, but are not limited to, polypropylene, polyester, polyethylene, polymethylmethacrylate, epoxy resin, silk, nylon and glass.
  • a resorbable composite comprising a first resorbable suture and a second resorbable suture, wherein the first resorbable suture is made of a material different than the second resorbable suture, and wherein at least one of the sutures is coated with a therapeutic agent, preferably a growth factor.
  • a therapeutic agent preferably a growth factor.
  • each suture is coated with the growth factor.
  • the growth factor is a BMP. More preferably, the growth factor is rhGDF-5.
  • one of the resorbable sutures is PLGA.
  • a partially resorbable composite comprising a first resorbable suture and a second non-resorbable suture, wherein at least one of the sutures is coated with a growth factor.
  • each suture is coated with the growth factor, wherein the growth factor is preferably a BMP. More preferably, the growth factor is rhGDF-5.
  • the resorbable suture is polydioxanone and the non-resorbable suture is polyethylene. More preferably, the growth factor is coated upon the composite suture disclosed in US Published Patent Application No. US 2005/0149118 (Koyfman), the specification is incorporated by reference in its entirety. In some embodiments, this composite is ORTHOCORD, available from Mitek, Raynham, MA.
  • a non-resorbable composite comprising a first non-resorbable suture and a second non-resorbable suture, wherein the first non-resorbable suture is made of a material different than the second non- resorbable suture, and wherein at least one of the sutures is coated with a therapeutic agent, preferably a growth factor.
  • a therapeutic agent preferably a growth factor.
  • each suture is coated with the growth factor.
  • the growth factor is a BMP. More preferably, the growth factor is a rhGDF-5.
  • the first non-resorbable suture is _a polyethylene core
  • the second non-resorbable suture is a polyester braided jacket.
  • the growth factor is coated upon the composite suture disclosed in US Patent No. 6,716,234 ("Grafton"), the specification is incorporated by reference in its entirety.
  • this composite is FIBERWIRE, available from Arthrex, Naples, FL.
  • growth factors encompasses any cellular product that modulates the adhesion, migration, proliferation, or differentiation of other cells, particularly connective tissue progenitor cells.
  • the growth factors that may be used in accordance with the present invention include, but are not limited to, members of the fibroblast growth factor family, including acidic and basic fibroblast growth factor (FGF- 1 and -2) and FGF-4, members of the platelet-derived growth factor (PDGF) family, including PDGF-AB, PDGF-BB and PDGF-AA; EGFs, members of the insulin-like growth factor (IGF) family, including IGF-I and -II; the TGF- ⁇ superfamily, including TGF- ⁇ 1 , 2 and 3 (including rhGDF-5), osteoid-inducing factor (OIF), angiogenin(s), endothelins, hepatocyte growth factor and keratinocyte growth factor; members of the bone morphogenetic proteins (BMP's) BMP-1 , (BMP's) B
  • the growth factor is GDF-5, preferably rhGDF-5. More preferably, the rhGDF-5 is administered using a solution with concentrations between 10 ng/mL and 40 mg/mL, more preferably between 100 ng/mL and 5 mg/mL, more preferably between 1 Dg/mL and 1 mg/mL.
  • the surgeon may want to coat just a portion of the suture. In others, the surgeon may want to insure that the suture has been evenly coated with the growth factor. In others, the surgeon may want to know simply when the suture has been sufficiently coated so that additional application of an expensive therapeutic agent is not required. These desires can be realized if the surgeon were able to see the extent to which the suture has been coated. Accordingly, in some embodiments, a dye may be added to the coating solution so that the surgeon can visualize the extent to which the suture has been coated. Suitable dyes include but are not limited to isosulfan blue (which has been used to visualize lymph nodes in breast cancer patients) and India ink.
  • a device 320 for coating a suture comprising:
  • a vessel 321 having an open end 323, a closed end 325 and an inner wall 327, b) a porous body 329 (such as a sponge) enclosing the open end of the vessel; c) a breakable seal 331 disposed upon the inner wall of the vessel defining a first chamber 333 and a second chamber 335 , d) a fluid 337 contained within the second chamber, and e) a therapeutic agent 339 contained within or on the porous body.
  • a porous body 329 such as a sponge
  • lyophilized rhGDF-5 is the therapeutic agent that is placed within the porous body.
  • the second chamber contains a predetermined volume of a fluid such as sterile saline or a thermoreversible gel.
  • a fluid such as sterile saline or a thermoreversible gel.
  • the flexible vial is squeezed at the location of the breakable seal, thereby breaking the seal between the two chambers and allowing fluid communication between the two chambers.
  • the vial is gently inverted to allow the fluid (such as saline) to enter the first chamber and soak into the porous body (preferably a domed sponge similar to that of a DERMABOND R applicator).
  • the rhGDF-5 contained within the porous body is solubilized.
  • the rhGDF-5 solution is then released onto a suture 315 by placing pressure on the domed sponge.
  • the rhGDF-5 solution is released onto the sutures by applying constant pressure to the sponge. This ensures an even coverage of the suture.
  • the sutures are then air-dried to remove the water from the solution, thereby leaving rhGDF-5 adhered to the suture.
  • the coated suture can then be used immediately for surgery.
  • the sponge has a rounded outer surface 330 for ease of use.
  • the coated sutures of the present invention can be used in repairing defects in soft tissue repairs, and in particular repairing a defect in a soft tissue selected from the group consisting of a ligament (such as an anterior cruciate ligament and a medial collateral ligament), a meniscus, tendons such as an Achilles tendon, an annulus fibrosus of an intervertebral disc, and a rotator cuff.
  • a ligament such as an anterior cruciate ligament and a medial collateral ligament
  • tendons such as an Achilles tendon
  • an annulus fibrosus of an intervertebral disc an intervertebral disc
  • a rotator cuff a rotator cuff
  • a method of repairing a soft tissue defect comprising the steps of: a) providing a defect in a soft tissue selected from the group consisting of a ligament (such as an anterior cruciate ligament and a medial collateral ligament), a meniscus, an annulus fibrosus of an intervertebral disc, and a rotator cuff, and b) advancing a suture coated with a therapeutic agent through the defect.
  • a ligament such as an anterior cruciate ligament and a medial collateral ligament
  • a meniscus such as an anterior cruciate ligament and a medial collateral ligament
  • an annulus fibrosus of an intervertebral disc such as an anterior cruciate ligament and a medial collateral ligament
  • a rotator cuff such as an anterior cruciate ligament and a medial collateral ligament
  • a method of repairing an Achilles tendon comprising the steps of: a) providing a defect in a tendon (such as an Achilles tendon), and b) advancing a suture coated with a therapeutic agent through the defect,
  • the therapeutic agent is selected from the group consisting of BMP-2, BMP-7, butyric acid, OP-1 , VEGF and PDGF.
  • any number of medical devices or implants may benefit by being coated with the coatings of this invention incorporated therewith to enhance the function and/or life of the device or implant.
  • Other medical devices which often fail due to tissue in-growth or accumulation of proteinaceous material in, on and around the device, such as stents, dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers and implantable defibrillators can also benefit from the coatings of this invention.
  • Devices which serve to improve the structure and function of tissue or organ may also show benefits when combined with the appropriate agent or agents.
  • improved osteointegration of orthopedic devices to enhance stabilization of the implanted device could potentially be achieved by combining it with agents such as bone-morphogenic protein.
  • agents such as bone-morphogenic protein.
  • sutures, staples, fasteners, vertebral motion discs, vertebral fusion cages and meshes, hooks, rods, pedicle screws, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings, bone substitutes, intraluminal devices, and vascular supports could also provide enhanced patient benefit using coatings of this invention.
  • any type of medical device may be coated in some fashion with coatings of this invention which enhance treatment over use of the singular use of the device or implant.
  • EXAMPLE I A 4-0 VICRYL (Polyglactin 910) Suture (Ethicon, Somerville, NJ) was coated with rhGDF-5 and gelatin.
  • the coating solution comprised of 4ml gelatin solution and 2ml of rhGDF-5 growth factor solution.
  • the gelatin component was prepared by heating a 10wt% solution of medical grade soluble bovine collagen (Semed-S, Kensey- Nash, Exton, PA) to 80 Q C for 10 minutes followed by incubation at 37 Q C.
  • rhGDF-5 Biopharm GmbH, Heidelberg, Germany
  • the resulting concentrations in the coating solutions were 1000, 200, and 0 Dg/ml, respectively.
  • the coating solutions were kept at 37 9 C until use.
  • the sutures Prior to coating, the sutures were pretreated with a bath of 70% ethanol solution for 10 minutes, followed by a wash with saline. The suture was then placed in the coating solution and incubated at 37 9 C for 30 minutes with gentle agitation. The suture was then removed from the solution and was then air-dried overnight.
  • the concentration of rhGDF-5 on the suture was quantified by an ELISA method.
  • the growth factor was first eluted from a 4cm segment of suture in 2ml of 6M Urea solution (75 mM NaH 2 PO 4 , pH 2.7) at 37 e C for 1 hour.
  • the elution solutions were analyzed by sandwich ELISA (Biopharm GmbH, Heidelberg, Germany) that detects rhGDF-5.
  • the concentration of rhGDF-5 on the suture was presented in Dg/cm. The results are presented in Table I.
  • Table 1 ELISA quantification of rhGDF-5 on gelatin/rhGDF-5 coated suture.
  • a 0 ETHIBOND EXCEL Polyester Suture (Ethicon, Somerville, NJ) was coated with rhGDF-5 and gelatin in a similar manner as described in Example I.
  • a rhGDF-5 solution was concentrated to 30 mg/ml with a centrifugal filter device (Centriplus YM- 10, Regenerated Cellulose 10,000 MWCO, Amicon Bioseparations).
  • the coating solution comprised of 0.5ml concentrated rhGDF-5 solution and 1ml 10wt% gelatin solution.
  • the concentration of rhGDF-5 on the coated suture, as quantified by ELISA, was 6.5 Dg/cm.
  • a 0 Plain Surgical Gut Suture (Ethicon, Somerville, NJ) was coated with rhGDF-5.
  • the coating solution comprised of 1ml rhGDF-5 solution concentrated to 13.9 mg/ml with a centrifugal filter device (Centriplus YM-10, Regenerated Cellulose 10,000 MWCO, Amicon Bioseparations).
  • the gut suture was pretreated in a bath of 200 mM NaH 2 PO 4 (pH 11.2) for 10 minutes followed by a wash in PBS prior to coating.
  • Example II DePuy Mitek, Raynham, MA was coated with rhGDF-5 and gelatin in a similar manner as described in Example I.
  • the coating solution comprised of 0.7ml rhGDF-5 growth factor solution at a concentration of 3.5 mg/ml and 1.4ml 10wt% gelatin solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Cette invention concerne un enrobage peropératoire de sutures avec des protéines thérapeutiques, plus particulièrement, des facteurs de croissance, tels que rhGDF-5. Le procédé décrit dans cette invention consiste à mettre en contact une suture et un dispositif contenant un agent thérapeutique. Cette invention concerne également des méthodes permettant de réparer des tissus mous endommagés au moyen de sutures enrobées et de sutures composites enrobées avec des agents thérapeutiques.
PCT/US2006/023017 2005-06-15 2006-06-13 Procede permettant un enrobage peroperatoire d'agents therapeutiques sur des sutures, sutures composites, et procedes d'utilisation associes WO2006138320A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/153,285 2005-06-15
US11/153,285 US20060286289A1 (en) 2005-06-15 2005-06-15 Method of intraoperative coating therapeutic agents onto sutures
US11/315,793 US20060287675A1 (en) 2005-06-15 2005-12-22 Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use
US11/315,905 US20060287676A1 (en) 2005-06-15 2005-12-22 Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US11/315,793 2005-12-22
US11/315,905 2005-12-22

Publications (2)

Publication Number Publication Date
WO2006138320A2 true WO2006138320A2 (fr) 2006-12-28
WO2006138320A3 WO2006138320A3 (fr) 2009-04-16

Family

ID=37571076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/023017 WO2006138320A2 (fr) 2005-06-15 2006-06-13 Procede permettant un enrobage peroperatoire d'agents therapeutiques sur des sutures, sutures composites, et procedes d'utilisation associes

Country Status (1)

Country Link
WO (1) WO2006138320A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114259A4 (fr) * 2007-02-14 2015-09-16 Mimosa Medical Inc Méthode and système de fixation de tissus
WO2017096403A1 (fr) * 2015-12-03 2017-06-08 Kinney Ramsey Système de suture revêtue permettant d'améliorer la réparation et la reconstruction de tissu mou
CN115089757A (zh) * 2022-07-28 2022-09-23 单县华宇缝合制品有限公司 自降解型的缝合线的加工工艺方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055759A1 (en) * 2000-11-06 2002-05-09 Shibuya Terry Y. Bioactive surgical suture

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055759A1 (en) * 2000-11-06 2002-05-09 Shibuya Terry Y. Bioactive surgical suture

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114259A4 (fr) * 2007-02-14 2015-09-16 Mimosa Medical Inc Méthode and système de fixation de tissus
WO2017096403A1 (fr) * 2015-12-03 2017-06-08 Kinney Ramsey Système de suture revêtue permettant d'améliorer la réparation et la reconstruction de tissu mou
CN115089757A (zh) * 2022-07-28 2022-09-23 单县华宇缝合制品有限公司 自降解型的缝合线的加工工艺方法

Also Published As

Publication number Publication date
WO2006138320A3 (fr) 2009-04-16

Similar Documents

Publication Publication Date Title
US20060287676A1 (en) Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US20060287675A1 (en) Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use
US20060286289A1 (en) Method of intraoperative coating therapeutic agents onto sutures
US20070224237A1 (en) Barbed sutures having a therapeutic agent thereon
EP3481445B1 (fr) Méthode indirecte de réparation de tissus articulaires
JP5484047B2 (ja) 回旋筋腱板傷害を処置するためのｐｄｇｆ−生体マトリックス組成物および方法
CN109276348B (zh) 用于封装骨材料的骨植入物
Panseri et al. Osteochondral tissue engineering approaches for articular cartilage and subchondral bone regeneration
US7300439B2 (en) Porous resorbable graft fixation pin
US5660225A (en) Method of fracture treatment by restraining macromolecules or macromolecular aggregates adjacent to damaged tissues
US8048857B2 (en) Flowable carrier compositions and methods of use
US20090177229A1 (en) Suture anchor with drug/growth factor delivery reservoir
JP2019520900A5 (fr)
CN108697507B (zh) 脊柱植入物系统和方法
US20070112360A1 (en) Bioprosthetic device
CN101094693B (zh) 产品无菌填充的方法和试剂盒
CN111278478A (zh) 用于锚固植入式医疗装置的套件
JP2019018006A (ja) 網を有する骨インプラント
CN101420923A (zh) 医用植入物和诱导纤维变性的试剂
CN113908339B (zh) 修复肩袖假体及其制备方法和修复肩袖假体装置
WO2006138320A2 (fr) Procede permettant un enrobage peroperatoire d'agents therapeutiques sur des sutures, sutures composites, et procedes d'utilisation associes
CN111867561A (zh) 可注射骨形态发生蛋白
WO2007112026A2 (fr) Livraison localisée d'un agent thérapeutique par les agrafes à arrêtes
US9339587B2 (en) Composition and methods for repair of connective tissue
Piontek et al. Biomaterials in Meniscus Repair

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06784834

Country of ref document: EP

Kind code of ref document: A2